{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:59:08Z","timestamp":1788479948123,"version":"build-2803163510"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression. Homologous recombination deficiency (HRD), which damages cells through absent or erroneous repair of double-stranded DNA breaks, is a prime example of such cellular dysfunction. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit these aberrancies in the cellular repair process by arresting the ability of the PARP enzyme to repair cellular and genetic damage, inducing the accumulation of DNA damage and cancer cell death. While the utility of PARP inhibitors has been established in many HRD-associated tumors \u2014 particularly breast, pancreatic, ovarian, and prostate cancer \u2014 less robust evidence exists for the efficacy of PARP inhibitors in melanoma. Increasing efforts are underway to investigate PARP inhibitors as a viable treatment option for advanced and metastatic melanoma, both as monotherapy and in combination with other agents such as immune checkpoint inhibitors and BRAF\/MEK inhibitors. Though several gaps in our knowledge of the use of PARP inhibitors in melanoma still exist, promising headway is being made in our understanding of its efficacy and safety. Here, we present a review of the utility of PARP inhibitors in melanoma, current clinical trials, and future avenues for further exploration.<\/jats:p>","DOI":"10.3389\/fonc.2025.1552386","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:25Z","timestamp":1754453545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["PARP inhibitors in melanoma treatment: potential, challenges, and future directions"],"prefix":"10.3389","volume":"15","author":[{"given":"Angela","family":"Anaeme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah N.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Nassief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ansstas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/cancers12041050","article-title":"DNA damage\/repair management in cancers","volume":"12","author":"Alhmoud","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B3","unstructured":"Mutation, DNA repair, and DNA integrity\n          \n          \n            \n              Clancy\n              S\n            \n          \n          New York\n          Nature Education\n          Learn Science at Scitable\n          \n          2008"},{"key":"B4","unstructured":"Performance and clinical utility of homologous recombination deficiency (HRD) determined by genome-wide loss of heterozygosity (LOH)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"10497","DOI":"10.3390\/ijms241310497","article-title":"HRD testing of ovarian cancer in routine practice: what are we dealing with","volume":"24","author":"Kekeeva","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2094133","DOI":"10.1080\/2162402X.2022.2094133","article-title":"Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype","volume":"11","author":"van Wilpe","year":"2022","journal-title":"Oncoimmunology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.breast.2023.04.002","article-title":"Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score","volume":"69","author":"Feng","year":"2023","journal-title":"Breast."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: A systematic review and prevalence meta-analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"10771","DOI":"10.3390\/ijms241310771","article-title":"Homologous recombination deficiency (HRD) in cutaneous oncology","volume":"24","author":"Akinjiyan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1758835919849753","DOI":"10.1177\/1758835919849753","article-title":"Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer","volume":"11","author":"Ledermann","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: the first synthetic lethal targeted therapy","volume":"355","author":"Lord","year":"2017","journal-title":"Science."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B19","doi-asserted-by":"crossref","unstructured":"Chapter 1 - Overview of DNA repair pathways, current targets, and clinical trials bench to clinic\n          \n          54\n          \n            \n              Kelley\n              MR\n            \n            \n              Fishel\n              ML\n            \n          \n          \n            \n              Kelley\n              MR\n            \n            \n              Fishel\n              ML\n            \n          \n          Boston\n          Academic Press\n          DNA repair in cancer therapy\n          \n          2016","DOI":"10.1016\/B978-0-12-803582-5.00001-2"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/pcmr.12833","article-title":"Melanoma predisposition\u2014A limited role for germline BRCA1 and BRCA2 variants","volume":"33","author":"Adams","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13578-020-00390-7","article-title":"The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review","volume":"10","author":"Patel","year":"2020","journal-title":"Cell Biosci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: A review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecologic Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"B27","unstructured":"Silver Spring, Maryland, United States\n          FDA\n          Research C for DE and. FDA approves niraparib for HRD-positive advanced ovarian cancer\n          \n          2024"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S360444","article-title":"Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res Rep Urol."},{"key":"B29","unstructured":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.012","article-title":"Phase\u00a03\u00a0MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate\u00a0and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations","volume":"40","author":"Chi","year":"2022","journal-title":"JCO"},{"key":"B31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32979","article-title":"Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice","volume":"126","author":"Nishikawa","year":"2020","journal-title":"Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"A randomized phase ib\/II study of niraparib plus nivolumab or ipilimumab in patients with platinum-sensitive advanced pancreatic cancer","author":"Reiss","year":"2022","journal-title":"Lancet Oncol"},{"key":"B34","unstructured":"Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.3390\/cancers15112955","article-title":"Pancreatic cancer: BRCA targeted therapy and beyond","volume":"15","author":"Keane","year":"2023","journal-title":"Cancers (Basel)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jid.2021.01.024","article-title":"Prevalence of homologous recombination pathway gene mutations in melanoma: rationale for a new targeted therapeutic approach","volume":"141","author":"Kim","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"PO.17.00286","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e15073","article-title":"Frequency of homologous recombination deficiency gene mutations in melanoma and its relevance to the immunotherapeutic response","volume":"39","author":"Liu","year":"2021","journal-title":"JCO."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03781-6","article-title":"The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors","volume":"148","author":"Kim","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"688","DOI":"10.6004\/jnccn.2022.7102","article-title":"Determining PARP inhibition as a treatment strategy in melanoma based on homologous recombination deficiency-related loss of heterozygosity","volume":"21","author":"Zhou","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.602","article-title":"Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade","volume":"32","author":"Khaddour","year":"2021","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"a006129","DOI":"10.1101\/mcs.a006129","article-title":"Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency","volume":"7","author":"Khaddour","year":"2021","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-024-00684-w","article-title":"Efficacy of PARP inhibitor therapy after targeted BRAF\/MEK failure in advanced melanoma","volume":"8","author":"Phillipps","year":"2024","journal-title":"NPJ Precis Onc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/cancers12061502","article-title":"Combined PARP inhibition and immune checkpoint therapy in solid tumors","volume":"12","author":"Peyraud","year":"2020","journal-title":"Cancers (Basel)."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.3390\/cancers13184520","article-title":"PARP inhibitors in melanoma\u2014An expanding therapeutic option","volume":"13","author":"Chan","year":"2021","journal-title":"Cancers."},{"key":"B47","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3892\/etm.2023.12115","article-title":"Advances in targeted therapy and immunotherapy for melanoma (Review)","volume":"26","author":"Qin","year":"2023","journal-title":"Exp Ther Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jdcr.2024.04.005","article-title":"Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification","volume":"48","author":"Nassief","year":"2024","journal-title":"JAAD Case Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-01007-6","article-title":"Advanced acral melanoma therapies: current status and future directions","volume":"23","author":"Zhang","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"B50","article-title":"Acral lentiginous melanoma","volume-title":"StatPearls","author":"Hall","year":"2024"},{"key":"B51","unstructured":"Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms\n          \n          39626160"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.12.005","article-title":"Uveal melanoma in BAP1 tumor predisposition syndrome: estimation of risk","volume":"224","author":"Singh","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0547-z","article-title":"Clinical pharmacokinetics and mass balance of veliparib in combination with temozolomide in subjects with nonhematologic Malignancies","volume":"57","author":"Nuthalapati","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.8","article-title":"A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours","volume":"104","author":"Khan","year":"2011","journal-title":"Br J Cancer."},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102499","article-title":"Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome","volume":"113","author":"Ziogas","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43556-024-00182-2","article-title":"Heterogeneity and molecular landscape of melanoma: implications for targeted therapy","volume":"5","author":"Beigi","year":"2024","journal-title":"Mol Biomed"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0101","article-title":"PARP inhibitors effectively reduce MAPK inhibitor resistant melanoma cell growth and synergize with MAPK inhibitors through a synthetic lethal interaction in vitro and in vivo","volume":"3","author":"Fr\u00f6hlich","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B58","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19075-3","article-title":"Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1\/2-mediated reactivation of MEK\/ERK\/MYC signaling","volume":"11","author":"Tripathi","year":"2020","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/genes12060845","article-title":"ATM: main features, signaling pathways, and its diverse roles in DNA damage response, tumor suppression, and cancer development","volume":"12","author":"Phan","year":"2021","journal-title":"Genes."},{"key":"B60","unstructured":"Phase II study of olaparib and pembrolizumab in advanced melanoma with homologous recombination (HR) mutation - NCI\n          \n          2016"},{"key":"B61","year":"2023","journal-title":"Fluzoparib in combination with camrelizumab and temozolomide in advanced melanoma (NCT05983237)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310497","article-title":"Hematological toxicities in\u00a0PARP inhibitors: A real-world study using FDA adverse event reporting system\u00a0(FAERS) database - Shu","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1626","article-title":"Exposure-safety analyses of talazoparib in patients with advanced breast cancer and germline BRCA1\/2 mutations in the EMBRACA and ABRAZO trials","volume":"60","author":"Elmeliegy","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"101154","DOI":"10.1016\/j.esmoop.2023.101154","article-title":"Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis","volume":"8","author":"Palazzo","year":"2023","journal-title":"ESMO Open"},{"key":"B65","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/ijms23158412","article-title":"PARP inhibitors: clinical limitations and recent attempts to overcome them","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2023.02.014","article-title":"Mechanism of PARP inhibitor resistance and potential overcoming strategies","volume":"11","author":"Fu","year":"2023","journal-title":"Genes Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.12.015","article-title":"Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients","volume":"160","author":"Liang","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.12.039","article-title":"The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: who bears the cost","volume":"160","author":"Goldsberry","year":"2021","journal-title":"Gynecol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1552386\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:31Z","timestamp":1754453551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1552386\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":68,"alternative-id":["10.3389\/fonc.2025.1552386"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1552386","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1552386"}}